| Assay ID | Title | Year | Journal | Article |
|---|
| AID1852915 | Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate preincubated for 30 mins followed by substrate addition and measured by malachite green based colorimetric assay relative to | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852917 | Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate preincubated for 30 mins in presence of 1 mM DTT followed by substrate addition and measured by malachite green based colori | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852916 | Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate and measured by malachite green based colorimetric assay relative to control | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852921 | Inhibition of Mycobacterium tuberculosis MetAP1a assessed as residual activity at 625 uM using L-methionine 7-amido-4-methylcoumarin as fluorogenic substrate and measured by fluorescence based assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852920 | Inhibition of recombinant SARS-CoV-2 3CLpro expressed in Escherichia coli NiCo21(DE3) assessed as residual activity at 500 uM using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins in presence of 1mM DTT followed by substrate addition and | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852922 | Inhibition of recombinant Escherichia coli DdlB assessed as residual activity at 500 uM using D-alanine as substrate incubated for 20 mins and measured by malachite green based colorimetric assay relative to control | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852924 | Redox activity of compound assessed as redox index at 100 uM measured by HRP-PR assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID404423 | Inhibition of nNOS assessed as conversion of L-[3H]arginine to L-[3H]citrulline | 2008 | Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
| Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. |
| AID1852925 | Redox activity of compound assessed as redox index at 100 uM in presence of 1 mM DTT measured by HRP-PR assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852927 | Redox activity of compound assessed as redox index at 100 uM in presence of 100 uM TCEP measured by H2DCFDA assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852926 | Redox activity of compound assessed as redox index at 100 uM measured by H2DCFDA assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852923 | Aqueous stability of the compound at pH 7.4 measured after 60 mins by spectrophotometric analysis | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852931 | Thiol reactivity of compound measured by TNB2- assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852930 | Thiol reactivity of compound at 100 uM measured by DTNB assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852919 | Inhibition of recombinant SARS-CoV-2 3CLpro expressed in Escherichia coli NiCo21(DE3) assessed as residual activity at 500 uM using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins followed by substrate addition and measured by FRET assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852928 | Redox activity of compound assessed as redox index at 10 uM measured by resazurin assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| AID1852929 | Redox activity of compound assessed as redox index at 1 uM measured by resazurin assay | 2022 | ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
| Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |